STOCK COMPARISON
Shandong Weigao Blood vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Shandong Weigao Blood (603014) and Abbott Laboratories (ABT) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Shandong Weigao Blood trades at ¥34.19 versus a fair value of ¥19.63 (-43%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Shandong Weigao Blood
603014.SHG · CNY · Healthcare
-43%
upside to fair value
overvalued
Price¥34.19
Fair Value¥19.63
Quality51/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Shandong Weigao BloodAbbott Laboratories
Valuation
28.5×P/E (TTM)27.7×
3.78×P/S (TTM)3.89×
2.01×P/B3.36×
16.0×EV/EBITDA15.1×
—PEG1.47×
1.5%Dividend yield—
¥0.52Dividend per share—
Profitability
13%Net margin14%
15%Operating margin13%
8%Return on equity12%
4%Return on assets6%
Growth
1%Revenue growth (YoY)8%
3.2%Avg. growth/yr (3Y)0.5%
—Avg. growth/yr (5Y)5.1%
Balance & size
—Debt / equity0.19×
$2BMarket cap$175B
healthyGrowth qualityhealthy
Abbott Laboratories leads: 4 to 6 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Shandong Weigao Bloodof which business quality 55 · market factors 34
Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
39
50
Quality GrowthAre margins and returns improving?
29
47
CashflowEarnings quality: real cash, not paper profit
75
71
Fin. StrengthBalance sheet, leverage, solvency risk
92
80
InvestmentDisciplined investing over empire-building
53
65
Low VolatilityCalm price path (market factor)
52
83
MomentumPrice trend over the last 3–12 months (market factor)
28
40
52W MomentumDistance to the 52-week high (market factor)
24
33
Net IssuanceBuybacks instead of dilution
20
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Shandong Weigao Blood
DCF Models¥26.91
Earnings-Based¥15.50
Dividend Discount¥2.40
Multiples¥22.11
Asset-Based¥11.42
Growth DCF¥25.42
Economic Profit¥14.89
Growth Earnings¥18.99
25 of 25 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Shandong Weigao Blood
Bear ¥14.59Fair Value ¥19.63Bull ¥24.53
¥34.19 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Shandong Weigao Blood · Healthcare
Quality score51 · above median
Fair value upside-43% · below median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Shandong Weigao Blood trades at ¥34.19 versus a fair value of ¥19.63 (-43%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
